Literature DB >> 19773793

Acute coronary syndromes: oral factor Xa inhibitors in acute coronary syndromes.

Luke Tapp, Ben Wrigley, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19773793     DOI： 10.1038/nrcardio.2009.160

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  8 in total

1.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Authors:  Giancarlo Agnelli; Alexander Gallus; Samuel Z Goldhaber; Sylvia Haas; Menno V Huisman; Russel D Hull; Ajay K Kakkar; Frank Misselwitz; Sebastian Schellong
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

3.  Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.

Authors:  Michael B Rothberg; Carmel Celestin; Louis D Fiore; Elizabeth Lawler; James R Cook
Journal:  Ann Intern Med       Date:  2005-08-16       Impact factor: 25.391

4.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

5.  Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Authors:  J L Mega; E Braunwald; S Mohanavelu; P Burton; R Poulter; F Misselwitz; V Hricak; E S Barnathan; P Bordes; A Witkowski; V Markov; L Oppenheimer; C M Gibson
Journal:  Lancet       Date:  2009-06-17       Impact factor: 79.321

6.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Authors:  H Buller; D Deitchman; M Prins; A Segers
Journal:  J Thromb Haemost       Date:  2008-06-06       Impact factor: 5.824

7.  Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

Authors:  John H Alexander; Richard C Becker; Deepak L Bhatt; Frank Cools; Filippo Crea; Mikael Dellborg; Keith A A Fox; Shaun G Goodman; Robert A Harrington; Kurt Huber; Steen Husted; Basil S Lewis; Jose Lopez-Sendon; Puneet Mohan; Gilles Montalescot; Mikhail Ruda; Witold Ruzyllo; Freek Verheugt; Lars Wallentin
Journal:  Circulation       Date:  2009-05-26       Impact factor: 29.690

8.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Authors:  Alexander G G Turpie; Michael R Lassen; Bruce L Davidson; Kenneth A Bauer; Michael Gent; Louis M Kwong; Fred D Cushner; Paul A Lotke; Scott D Berkowitz; Tiemo J Bandel; Alice Benson; Frank Misselwitz; William D Fisher
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.